Deep venous thrombosis, pulmonary embolism

Indication for Nadroparin

Population group: Suitable for both men and women, only adults (18 years old or older)

For this indication, competent medicine agencies globally authorize below treatments:

7,600-17,100 IU once daily

Route of admnistration


Defined daily dose

7,600 - 17,100 [iU]

Dosage regimen

From 7,600 To 17,100 [iU] once every day

Detailed description

Nadroparin should be injected subcutaneously once daily for the duration of 10 days in a dosage appropriately adjusted for the patient’s body weight (see Table below).

Weight in kg Treatment of deep venous thrombosis ml subcutaneous injection once daily
<500.4 ml
50 to 590.5 ml
60 to 690.6 ml
70 to 790.7 ml
80 to 890.8 ml
≥900.9 ml

Monitoring during treatment

Because of the risk of heparin-induced thrombocytopenia, the platelet count must be monitored regularly during treatment with nadroparin.

Checking the platelet count is recommended prior to initiating treatment, during the first day of treatment and subsequently every 3 to 4 days, as well as at the end of treatment.

Occasionally, a mild transient thrombocytopenia (Type I) with platelet counts between 100,000/microliter and 150,000/microliter (caused by transient platelet activation) occurs at the beginning of treatment. Complications generally do not occur in these cases. Treatment may, therefore, be continued.

Antibody-mediated severe thrombocytopenia (Type II) with platelet counts clearly below 100,000/microliter or a rapid drop to less than 50% of the initial value is rarely observed. In non-sensitized patients, platelet count decrease primarily starts 6 to 21 days after the onset of treatment; in sensitized patients, platelet count decrease may start within hours. The severe form of thrombocytopenia may be associated with arterial and venous thrombosis/thromboembolism, disseminated intravascular coagulation, and possible skin necrosis at the injection site, petechiae, purpura and melena. In such cases, nadroparin must be discontinued immediately and a different antithrombotic treatment must be considered. The patient must be informed that he or she may no longer use heparin-containing medications in the future.

Dosage considerations

For subcutaneous administration of nadroparin, the lateral abdominal wall is the usual site of injection. As an alternative, nadroparin can be injected into the thigh.

The needle is inserted perpendicularly into a fold of skin formed between the thumb and index finger that should be gently but firmly held until injection has been completed. The injection site should not be rubbed.

Active ingredient

Nadroparin is a low-molecular weight heparin. Nadroparin inhibits Factor Xa in particular and thrombin to a lesser extent. Inhibition is partially mediated via the plasma protease inhibitor antithrombin III. Nadroparin has less effect on platelet function and aggregation and only has a minor effect on primary haemostasis compared to heparin.

Read more about Nadroparin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner